International intraductal papillary mucinous neoplasms registry: Long-term results based on the new guidelines

M Moris, Massimo Raimondo, TA Woodward, VJ Skinner, PG Arcidiacono, MC Petrone, Claudio De Angelis, S Manfrè, S Carrara, M Jovani, Pietro Fusaroli, MB Wallace

Research output: Contribution to journalArticlepeer-review


Objective: The aim of this studywas to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. Methods: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. Results: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMNconsisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time ofmore than 5 years, and no malignancy was diagnosed. Conclusions: In IPMN lesions with low-risk features at baseline, the risk of progression tomalignancy after the first 5 years of follow-up wasminimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)306-310
Number of pages5
Issue number3
Publication statusPublished - 2017


Dive into the research topics of 'International intraductal papillary mucinous neoplasms registry: Long-term results based on the new guidelines'. Together they form a unique fingerprint.

Cite this